The Technical Analyst
Moleculin Biotech Inc [MBRX]
Exchange: NASDAQ Capital Market Sector: Healthcare Industry: Biotechnology
Stock Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: SELL (auto-tracking)
-7.15% $1.560
Last updated: 21 Jan 2022 @ 12:33 pm
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 44.58 mill |
| EPS: | -0.700 |
| P/E: | 0.000 |
| Earnings Date: | Mar 22, 2022 |
| SharesOutstanding: | 28.58 mill |
| Avg Daily Volume: | 0.280 mill |
| RATING 2022-01-20 |
|---|
| B+ |
| Buy |
| RATING DETAILS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Neutral | |
| Return On Asset: | Neutral | |
| DE: | Neutral | |
| P/E: | Strong Sell | |
| Price To Book: | Strong Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 2/20 | 3/20 | 4/20 | 1/21 | 2/21 | 3/21 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | n/a | n/a | n/a | n/a | n/a | n/a |
| Ebit | ||||||
| Asset | ||||||
| Debt |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$3.09 (98.03%) $1.529 |
| Date: 2022-01-21 |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2021-07-11 | Klemp Walter V | Buy | 13 205 | Common Stock |
| 2021-07-11 | Klemp Walter V | Sell | 13 205 | Restricted Stock Units |
| 2021-07-11 | Klemp Walter V | Sell | 3 215 | Common Stock |
| 2021-07-02 | Klemp Walter V | Buy | 14 718 | Common Stock |
| 2021-07-02 | Klemp Walter V | Sell | 14 718 | Restricted Stock Units |
| INSIDER POWER |
|---|
| 65.78 |
| Last 60 transactions |
| Buy: 6 335 349 | Sell: 333 241 |
Forecast:
14:10 - $1.542
Live Trading Signals (every 1 min)
Forecast 1: 12:40 - $1.553
Forecast 2: 13:30 - $1.556
Forecast 3: 14:10 - $1.542
SCORE
-10.00
Sell
-10.00
Sell
Score Algorithm Version: 1.0b
Last version updated: Wed 15th Dec 2021
Last version updated: Wed 15th Dec 2021
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $1.560 (-7.15% ) |
| Volume | 0.230 mill |
| Avg. Vol. | 0.280 mill |
| % of Avg. Vol | 82.01 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For MBRX
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
| Date | Signal | @ | Closed | % | Jan 21 - 17:10 | sell | $1.590 | N/A | Active |
|---|
MBRX
Moleculin Biotech, Inc. is a clinical stage pharmaceutical company, which focuses on the development of oncology drug candidates. The company is headquartered in Houston, Texas and currently employs 9 full-time employees. The firm is focused on the development of anti-cancer drug candidates. Its lead drug candidate is liposomal Annamycin, which it refers to as Annamycin, an anthracycline intended for the treatment of relapsed or refractory acute myeloid leukemia (AML). Annamycin is a Phase II clinical-stage anthracycline and liposome formulated anthracycline that has been designed to eliminate cardiotoxicity and avoid the multidrug resistance mechanisms. The company has over two other drug development projects in progress, one involving a portfolio of small molecules, which it refers to as the WP1066 Portfolio, focused on the modulation of key oncogenic transcription factors involved in the progression of cancer, and the WP1122 Portfolio, a suite of molecules targeting the metabolic processes involved in cancer in general, and glioblastoma. As of April 3, 2017, it had not generated any revenue from its operations.
Latest Press Releases
2022-01-18 08:05:00 - Press Release
Moleculin Announces Updated Preliminary Safety Data For Annamycin In Its Three Phase 1 Clinical Trials For Acute Myeloid Leukemia And Metastases Of Soft Tissue Sarcoma
Houston, jan. 18, 2022 /prnewswire/ -- moleculin biotech, inc. , (nasdaq: mbrx) ("moleculin" or the "company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today reported that it has received an updated independent safety review of certain preliminary data for the first 30 patients in its three phase 1 clinical trials with annamycin targeting relapsed or refractory acute myeloid leukemia (aml) and the metastases of soft tissue sarcoma to the lungs (sts lung), which concluded there was no evidence of cardiotoxicity. the review included analysis of ejection fraction, echo strain and certain troponin levels intended to assess potential for both acute and chronic heart damage.
2021-12-27 08:05:00 - Press Release
Moleculin Announces Preliminary Third Cohort Interim Data In Phase 1b/2 Clinical Trial Of Annamycin For The Treatment Of Soft Tissue Sarcoma Lung Metastases
Houston, dec. 27, 2021 /prnewswire/ -- moleculin biotech, inc. , (nasdaq: mbrx) ("moleculin" or the "company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today reported preliminary interim results from its u.s. phase 1b/2 clinical trial as it concluded the safety review of the third cohort and opens the fourth cohort in a dose escalation trial evaluating annamycin for the treatment of soft tissue sarcoma (sts) lung metastases, which continues to document preliminary clinical activity for this drug. the phase 1b/2 study is a u.s. multi-center, open-label, single-arm study that in phase 1b will determine the maximum tolerated dose (mtd) or the recommended phase 2 dose (rp2d) and safety of annamycin.
2021-12-01 08:35:00 - Press Release
Moleculin Receives Fda Allowance To Begin A Phase 1 Study Of Wp1122 For The Treatment Of Glioblastoma Multiforme
Houston, dec. 1, 2021 /prnewswire/ -- moleculin biotech, inc., (nasdaq: mbrx) (moleculin or the company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that the us food and drug administration (fda) is allowing the company's investigational new drug (ind) application to study wp1122 for the treatment of glioblastoma multiforme (gbm) to go forward. with this ind now cleared, moleculin plans to initiate a phase 1 open label, single arm, dose escalation study of the safety, pharmacokinetics and efficacy of oral wp1122 in adult patients with gbm.
2021-11-11 08:05:00 - Press Release
Moleculin Reports Third Quarter 2021 Financial Results And Provides Programs Update
Houston, nov. 11, 2021 /prnewswire/ -- moleculin biotech, inc., (nasdaq: mbrx) (moleculin, we or the company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today reported its financial results for the quarter ended september 30, 2021. the company also provided an update on its portfolio of oncology drug candidates for the treatment of highly resistant tumors and viruses.
2021-10-19 09:05:00 - Press Release
Moleculin Receives Authorization From The Medicines And Healthcare Products Regulatory Agency (mhra) To Commence Phase 1a Clinical Trial Of Wp1122 For The Treatment Of Covid-19
Houston, oct. 19, 2021 /prnewswire/ -- moleculin biotech, inc., (nasdaq: mbrx) (moleculin or the company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced it has received authorization from the medicines and healthcare products regulatory agency (mhra) to commence a phase 1a clinical trial of wp1122 in the united kingdom. wp1122, the company's lead metabolism/glycosylation inhibitor, is a prodrug of a well-known antimetabolite called 2-deoxy-d-glucose (2-dg) currently being developed for inhibition of viral replication and disease manifestations in humans infected with sars-cov-2, the virus responsible for covid-19.
Latest News
2022-01-20 08:40:00 - PRNewsWire
Moleculin Biotech, Inc. to Present at the Virtual Investor 2022 Top Picks Conference
HOUSTON, Jan. 20, 2022 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that Walter V. Klemp, Founder, President, CEO and Chairman, will participate in the Virtual Investor 2022 Top Picks Conference on Thursday, January 27, 2022 at 9:00 AM ET.
2022-01-07 08:30:00 - PRNewsWire
Moleculin to Present at the H.C. Wainwright BioConnect Conference
HOUSTON, Jan. 7, 2022 /PRNewswire/ -- Moleculin Biotech, Inc. , (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that Walter Klemp, President and Chief Executive Officer of Moleculin, will present at the virtual H.C. Wainwright BioConnect Conference taking place January 10-13, 2022.
2021-12-01 14:08:18 - Benzinga
Read Why Is Roth Capital Bullish On This Cancer-Focused Stock
Roth Capital notes that the FDA cleared Moleculin Biotech Inc's (NASDAQ:MBRX) WP1122 to start a Phase 1 trial in glioblastoma multiforme, which will be in addition to the drug's impending parallel clinical development in COVID-19. Analyst Jonathan Aschoff expects several clinical data updates over the next year, with Moleculin Biotech potentially having six ongoing trials by year-end 2021.
2021-11-12 08:05:00 - PRNewsWire
Moleculin Biotech, Inc to Present at the Virtual Investor Roundtable Event
HOUSTON, Nov. 12, 2021 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that Walter V. Kemp, Founder, President, CEO and Chairman and Dr. John Paul Waymack, Senior Chief Medical Officer will participate in the Virtual Investor Roundtable Event on Thursday, November 18, 2021 at 11:00 AM ET.
2021-10-19 15:54:26 - Pulse2
MBRX Stock: Why It Increased Today
The stock price of Moleculin Biotech Inc (NASDAQ: MBRX) increased by over 2% during intraday trading today. This is why it happened.
2021-10-19 09:05:00 - PRNewsWire
Moleculin Receives Authorization from the Medicines and Healthcare Products Regulatory Agency (MHRA) to Commence Phase 1a Clinical Trial of WP1122 for the Treatment of COVID-19
HOUSTON, Oct. 19, 2021 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced it has received authorization from the Medicines and Healthcare Products Regulatory Agency (MHRA) to commence a Phase 1a clinical trial of WP1122 in the United Kingdom. WP1122, the Company's lead metabolism/glycosylation inhibitor, is a prodrug of a well-known antimetabolite called 2-deoxy-D-glucose (2-DG) currently being developed for inhibition of viral replication and disease manifestations in humans infected with SARS-CoV-2, the virus responsible for COVID-19.
2021-10-18 08:25:00 - PRNewsWire
Moleculin Announces Interim Data in Phase 1b/2 Clinical Trial of Annamycin for the Treatment of Soft Tissue Sarcoma Lung Metastases
HOUSTON, Oct. 18, 2021 /PRNewswire/ -- Moleculin Biotech, Inc. , (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today reported interim results from its U.S. Phase 1b/2 clinical trial evaluating Annamycin for the treatment of soft tissue sarcoma (STS) lung metastases, which documented preliminary clinical activity for Annamycin. The Phase 1b/2 study is a U.S. multi-center, open-label, single-arm study that in Phase 1b will determine the maximum tolerated dose (MTD) or the recommended Phase 2 dose (RP2D) and safety of Annamycin.
2021-09-27 07:05:00 - PRNewsWire
Moleculin to Present at the 2021 Cantor Virtual Global Healthcare Conference
HOUSTON, Sept. 27, 2021 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that Walter Klemp, President and Chief Executive Officer of Moleculin, will present at the 2021 Cantor Virtual Global Healthcare Conference on September 27, 2021 at 8:40 AM ET.
2021-09-17 08:05:00 - PRNewsWire
Moleculin to Present at the Oppenheimer Fall Healthcare Life Sciences and MedTech Summit
HOUSTON, Sept. 17, 2021 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that Walter Klemp, President and Chief Executive Officer of Moleculin, will present at the virtual Oppenheimer Fall Healthcare Life Sciences and MedTech Summit on September 20, 2021 at 4:35 PM ET.
2021-08-12 08:18:00 - PRNewsWire
Moleculin Reports Second Quarter 2021 Financial Results and Provides Programs Update
HOUSTON, Aug. 12, 2021 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced its financial results for the quarter ended June 30, 2021. The Company also provided an update on its portfolio of oncology drug candidates for the treatment of highly resistant tumors and viruses.